All posts by imreal

Healthcare and Public Safety to Get Free Employee Scheduling Software during COVID-19


employee scheduling software, nurse scheduling, officer scheduling, free software

ScheduleAnywhere Employee Scheduling Software

We’re proud to support mission-critical operations and essential services during this difficult and stressful time.

Atlas Business Solutions, Inc. (ABS) has launched a program to help support healthcare and public safety during the COVID-19 global pandemic. Any healthcare organization or public safety department not currently using ScheduleAnywhere can use it free through June 30, 2020. Current healthcare and public safety ScheduleAnywhere customers will be upgraded to an unlimited employee license through June 30, 2020 at no additional charge. This can be used to add other locations, departments or related services that can assist during this crisis.

“We’re proud to support mission-critical operations and essential services during this difficult and stressful time,” said Jon Forknell, vice president and general manager of ABS. “Now more than ever, they need a simple and effective way to manage and communicate work schedules.”

Thousands of healthcare entities and public safety departments rely on ScheduleAnywhere daily to make sure the right people are scheduled at the right time and place. Prior to using ScheduleAnywhere, most customers were scheduling by hand using a spreadsheet or some other time-consuming process. To help with the transition to ScheduleAnywhere, ABS is helping on-board employees and offering mini-training sessions at no additional cost.

“We know the last thing these folks need right now is to learn a new software program,” said Forknell. “We’re making it easy to get up and running and are here to provide free support when needed.”

About ScheduleAnywhere

ScheduleAnywhere is online employee scheduling software developed by Atlas Business Solutions, Inc. This Software as a Service (SaaS) works for any business that schedules shifts, including mission-critical operations like public safety and healthcare. The software ensures proper shift coverage, eliminates scheduling conflicts, tracks certifications and training, and manages shift rotations, staff availability, overtime and time-off requests. Free trial accounts are available and pricing is based on the number of employees scheduled.

About Atlas Business Solutions

Atlas Business Solutions, Inc. is a leading developer of easy-to-learn, easy-to-use, and affordable business management software. Founded in 1991, the company is recognized as an industry leader and was named as one of Software Magazine’s Top 500 Software Companies nine out of the last fifteen years.

Share article on social media or email:

EA Markets Adds Head of Financial Sponsor Advisory David Gilio


EA Markets LLC, an independent investment banking advisor providing capital arranging and financial advisory services, announced today the addition of David Gilio as Head of the firm’s Financial Sponsor Advisory practice.

David brings more than twenty years of experience in leveraged finance and capital markets. At EA, he will be responsible for expanding EA’s relationships with private equity firms and delivering EA’s unique capital markets capabilities in leveraged loans, high yield, direct placements, derivatives and securitizations.

Mr. Gilio began his investment banking career at Bank of America where he held senior private equity coverage and leveraged finance positions. Most recently, David spent seven years with BNP Paribas where he led Technology, Media & Telecom leveraged finance with private equity firms.

“David is an accomplished and highly successful leveraged finance banker with an extensive set of private equity relationships” commented Reuben Daniels, founder and Managing Partner of EA Markets. “His leverage finance expertise will be a meaningful resource for all of our financial sponsor clients.”

About EA Markets LLC (http://www.eamarkets.com)

EA Markets is an independent investment bank focused on arranging capital. EA has raised over $100 billion dollars in debt and equity financing for public corporations and private equity portfolio companies. Our corporate finance professionals are highly experienced in executing syndicated loans, direct placements and securities underwriting transactions. For more information about EA, visit the website at http://www.eamarkets.com.

Contact:     Joe Hoban

646-415-6143

http://www.eamarkets.com

Share article on social media or email:

GoShip.com Helps Small Businesses and Individuals While Donating All Profits for Two Months to the CDC Foundation


GoShip.com to Donate All Profits for April and May to CDC Foundation

We’re fortunate to be classified as an essential business and to be in a position to help others.

GoShip.com, a digital shipping platform, is donating 100% of its profits from April and May to help the response to COVID-19. GoShip will be donating the profits to the CDC Foundation’s Emergency Response Fund, which provides support to rapidly emerging response needs related to COVID-19.

As a 24/7 digital shipping platform, GoShip is open all the time and requires no face-to-face contact—which is particularly relevant with social distancing and stay-at-home orders throughout the United States. Featuring a user-friendly interface, customers can conveniently place orders anytime and anywhere in just a few minutes while saving up to 30% over some of the better-known shipping options. GoShip has relationships with more than 50,000 freight carriers, providing shippers of all sizes the most cost-competitive shipping solutions.

GoShip.com Director of Product Ramesh Chalapalli said, “We’re fortunate to be classified as an essential business and to be in a position to help others. GoShip has continued to experience record-setting volumes throughout the COVID-19 pandemic, and we are pleased to be able to give back to the medical community.”

GoShip.com is a digital shipping platform that allows shippers of all sizes to electronically book full-truckload (FTL) and less-than-truckload (LTL) shipments at the press of a button, while enjoying highly competitive rates that are unavailable to most non-Fortune 500 shippers.

For more information, visit http://www.GoShip.com. To download the GoShip.com app, visit the Apple Store or Google Play on your Apple or Android device.

# # #

NOTE: If you’d like to schedule an interview with officials at GoShip.com, please contact Jeff Krakoff at 412-709-4199 or jeffk@krakoffcomm.com.

Share article on social media or email:

Synthesizing Oligos Just Got Faster


Biolytic introduces the fastest, most efficient high throughput oligo synthesizer utilizing 2 x 384 well plates, the Dr. Oligo 768XLc.

Dr. Oligo 768XLc, the fastest, most efficient high throughput oligo synthesizer utilizing 2 x 384 well plates.

Biolytic’s novel patent pending system results is the highest possible chemical reaction efficiency

Biolytic Lab Performance, Inc. unveiled its novel oligo synthesizer, the Dr. Oligo 768XLc, the most commercially advanced platform for high throughput nucleic acid synthesis. Designed to be operated in both R&D and production facilities, it fits the needs of organizations focused on diagnostic and therapeutic applications for various viruses, diseases and conditions where large quantities of unique DNA and RNA are critical to their products, services and ongoing research.

Biolytic CEO and founder, Tom Demmitt, shared that the inspiration behind the Dr. Oligo 768XLc was to “accommodate industries innovating in diagnostic and therapeutic spaces and requiring state of the art oligos modified with non-standard bases.” Tom is confident that their new instrument will help Biolytic “play a crucial role in individualized medicine and immunotherapy worldwide.”

Ready to Run

The Dr. Oligo 768XLc includes fully tested protocols and initial 384-well synthesis media from 2 to 100 nmol per well for turn-key synthesis beginnings. Available with optional trityl collection, oligo desalting and elution capabilities.

Efficient Reactions

Biolytic’s novel patent pending system results is the highest possible chemical reaction efficiency using the minimum amount of reagents across our entire line of Dr. Oligo XLc instruments. Our system overcomes chemistry over consumption and reaction inconsistencies that are a result of well to well flow rate variability and other issues typical in high throughput synthesis media.

Features


  • Extremely Efficient Mixing of all reagents dispensed into each well using our patent pending system. The entire volume of reagent delivered to each reaction well is thoroughly mixed with the synthesis media resulting in optimal use of all reagent delivered.
  • Deliver only the volume of each reagent needed to obtain the optimal molar excess for achieving near 100% reaction efficiency.
  • A simplified design and layout resulting in easier operation and maintenance thus lowering operational costs.
  • Innovative hardware designs result in efficiencies never before achieved in high throughput oligo synthesis. This translates to lowering cost of synthesis by conserving very costly unique bases / specials when synthesizing innovative, unique oligos.
  • A new, patent pending nozzle system dispenses 16 nozzles simultaneously and eliminates complexities of previously available designs. This results in reduces maintenance and operating cost as well as contributing to faster synthesis time.
  • Powerful Production Software providing the ability to efficiently synthesize complex molecules in high throughput while reducing consumption of costly modified nucleotide building blocks.


About Biolytic

Founded in 1993, Biolytic® Lab Performance, Inc. designs and manufactures the most advanced oligo synthesizers and related lab accessories in the world. Alongside more than 25 years of experience in end-to-end synthesis processes and equipment coupled with their extensive knowledge and customer support has allowed Biolytic to continuously lead the oligo synthesis industry.

Customers all over the world use oligos produced by Biolytic Dr. Oligo synthesizers for their own unique purposes. From applications like gene synthesis, genetic diagnostic test kits, PCR/RT – PCR, siRNA,/RNAi, miRNA, CRISPR Cas9, anti-sense treatments and DNA/RNA sequencing – to broader areas like evolutionary history, forensics, immunotherapy, diagnostic and therapeutic research – to high-throughput screening, modified oligos, mixed backbones, LNAs and the visual detection of virus RNA such as COVID-19 following RT-LAMP amplification with DNA primers – the variety is tremendous. The Dr. Oligo line has evolved alongside cutting-edge discoveries. Biolytic anticipates that the 768XLc will take its place to play a significant role in modern science.

Media Contact: Biolytic Lab Performance, Inc. – (510) 795-1142 – media [at] biolytic [dot] com

For more information please visit http://www.biolytic.com

Share article on social media or email:

Encompass Group, LLC Quickly Responds to SONSIEL Urgent Call-to-Action on COVID-19


John Wood, CEO, Encompass Group, LLC

John Wood, CEO, Encompass Group, LLC

“Thank you to SONSIEL for finding creative ways to support our caregivers and all of the other heroes at the frontline of the COVID-19 battle.”

In the first of many consecutive efforts to respond to the national emergency to combat COVID-19, Encompass Group, LLC today announced a direct corporate donation through a national call-to-action program, SHARE, established and implemented by the Society of Nurse Scientists Innovators Entrepreneurs & Leaders (SONSIEL), in partnership with the GLO Good Foundation.

SONSIEL initiated SHARE—“Strengthen Healthcare Ability to Respond to Emergencies”—March 17, 2020 to instantly ignite community efforts to rapidly identify existing inventories of personal protective equipment (PPE) and move the urgently needed items to healthcare workers at high risk of infection. Through its network of professionals and volunteers, SONSIEL immediately called on non-hospital healthcare organizations and commercial businesses to help raise as much protective gear as possible, as quickly as possible, and to voluntarily move it into hot-spot areas. Within days, Encompass Group, LLC had committed to shipment of approximately 1,200 disposable jackets to assist frontline healthcare.

The Encompass Group, LLC SHARE donation was part of tens of thousands of pieces of protective gear conveyed from private and corporate donors to hospital healthcare staff in over a dozen hard-hit states. A March 20, 2020 ABC News NIGHTLINE episode featured SHARE program activity, with SONSIEL President & Co-Founder Rebecca C. Love and GLO Good Foundation Co-Founder Dr. Jonathan B. Levine. The NIGHTLINE story footage included jackets being packed and shipped out by Encompass Group, LLC.

Stated Rebecca C. Love, MSN, RN, SONSIEL President & Co-Founder, “Encompass Group, LLC was among the first organizations to say yes to our nationwide request for vitally needed PPE and we couldn’t be more grateful to the company and its hardworking people. Hundreds of frontline nurses, doctors, and technicians are working more safely today because of the swift decision to help by Encompass Group.”

Remarked John Wood, Encompass Group, LLC Chief Executive Officer, “We’re so happy we could help others by participating in the SHARE program. Credit goes to our staff, who set this up.”

Said Eric Howard, Encompass Group, LLC Vice President & General Manager, TECHStyles, “Encompass Group, LLC and our employees are fortunate to be in a position to be part of the solution during this difficult time. Thank you to SONSIEL for finding creative ways to support our caregivers and all of the other heroes at the frontline of the COVID-19 battle.”

Stay tuned for more news about Encompass Group, LLC efforts to respond to the national emergency to combat COVID-19. To learn more about Encompass Group, LLC, please visit https://www.encompassgroup.com. To support SONSIEL SHARE, visit https://bit.ly/GLOGoodxSONSIEL.

ABOUT ENCOMPASS GROUP, LLC

Encompass Group, LLC is one of the world’s leading manufacturers and marketers of reusable textiles, professional apparel, and disposable and single-use medical products. Encompass Group believes that every patient, resident, caregiver, and family member should feel safe and comfortable in today’s healthcare environments. Encompass Group enhances the healthcare experience by developing innovative products that are reliably delivered and cost-effective for all providers. Encompass Group serves the acute-care, long-term, and senior-care markets, retail healthcare and hospitality apparel markets, and government operations markets. For more information about Encompass Group, LLC, please visit https://www.encompassgroup.com.

Follow Encompass Group, LLC on LinkedIn at https://www.linkedin.com/company/encompass-group-llc/ (@encompass-group-llc); Twitter at https://twitter.com/EncompassGrpLLC (@EncompassGrpLLC); Facebook at https://www.facebook.com/EncompassGrpLLC (@EncompassGrpLLC); and YouTube at https://www.youtube.com/user/EncompassGroupLLC.

ABOUT SONSIEL

SONSIEL is a national and international platform of nurse scientists, innovators, and entrepreneurs, directly impacting health and the healthcare ecosystem through innovation and entrepreneurship; SONSIEL is a purpose-built society of nurses designed to create new opportunities and solutions across healthcare. Nurses are on the front lines, working with all healthcare team members to keep patients and the community safe. For more information about SONSIEL, please visit https://www.sonsiel.org/.

Follow SONSIEL on LinkedIn at https://www.linkedin.com/company/sonsiel/ (@SONSIEL); Twitter at https://twitter.com/SONSIEL2 (@SONSIEL2); Facebook at https://www.facebook.com/Sonsielnurse/ (@SONSIELnurse); Instagram at https://www.instagram.com/sonsielnurse/ (@SONSIELNURSE); and YouTube https://www.youtube.com/channel/UCpeapLA1QkY45l9NdOkxtQA/ (SONSIEL SONSIEL).

Share article on social media or email:



Commemorating The 30th Anniversary of Ryan White’s Death Due to HIV/AIDS Complications


The story of Ryan White's life, struggles and achievements are portrayed in the Power of Children exhibit at The Children's Museum of Indianapolis.

Ryan White and his mother, Jeanne White Ginder

It’s extremely important to pay attention to the medical evidence and listen to medical experts and let them be the ones who guide us—not rumor. We have a chance to do something right now to save lives and that’s to stay home.

In 1984, a teenager educated a frightened world about a deadly disease. Kokomo, Indiana native Ryan White was just 13-years-old when he contracted HIV/AIDS through a tainted blood product used to treat his hemophilia. There was widespread fear, ignorance and panic.

30 years later, the world is facing another horrible disease that is claiming lives, COVID-19. It is also causing fear and spreading panic around the world. Often, history teaches valuable lessons that can help with challenges faced today.

Following his diagnosis, White was banned from attending his high school classes. He wanted to live a normal life and attend school like all the other kids his age. But panic and fear gripped the nation. So, White’s family took the school to court to pursue Ryan’s right to attend classes. As his physical battle to fight the disease and the legal battle wore on, the White family moved to Cicero, Indiana where White was welcomed into Hamilton Heights High School. There, he made several new friends and earned his high school diploma. White’s influence spread to the entertainment industry. In fact, musician Elton John credits Ryan White with helping the singer turn his life around. Ryan died on April 8, 1990 from AIDS-related pneumonia at the young age of 18-years-old.

At the time, medical experts explained that HIV/AIDS was not spread through the air and that the disease was transmitted through tainted blood product, coming into direct contact with certain body fluids from a person with HIV such as blood, semen, and breast milk or from drug usage with tainted needles. Many people, however, did not understand or believe that. Ryan’s mother says things are not much different these days when it comes to disease. “There are a lot of similarities today with COVID-19 with how people are scared and everyone has an opinion on how you get the disease and how you don’t. It’s extremely important to pay attention to the medical evidence and listen to medical experts and let them be the ones who guide us—not rumor,” said Jeanne White Ginder. “We have a chance to do something right now to save lives and that’s to stay home.” White Ginder hopes people will work harder to be informed by the experts, make informed decisions as a result and show compassion. She went on to talk about how she still misses her son every day but is glad he made a huge difference in the world through the Ryan White Care Act, which provides a comprehensive system of HIV primary medical care, essential support services, and medications for people living with HIV to improve health outcomes and reduce HIV transmission among hard-to-reach populations. White Ginder has one regret, “We’ve not done our job by making the disease real to people. That was a big thing Ryan did. He made the disease real and it helped change lives.”

The Children’s Museum of Indianapolis proudly acquired all of the artifacts from Ryan’s teenage bedroom from his mother, Jeanne White Ginder. Under her watchful eye, the museum painstakingly recreated Ryan’s bedroom, which is part of the museum’s Power of Children permanent exhibit. She says some of Ryan’s happiest memories took place in that home, especially in his room filled with toy collections, posters and other memorabilia.

The world’s largest children’s museum is temporarily closed due to social gathering restrictions resulting from COVID-19; but, children and families can still learn more about Ryan White through a series of new blogs that can be found on The Children’s Museum website. Then when things return to normal, after the corona virus pandemic, Jeanne White Ginder plans to continue visiting Ryan’s room at The Children’s Museum of Indianapolis several times a year to share memories and stories about Ryan’s journey.

The courage and bravery of a young teenager fighting for his life and desire to be treated as a normal child is a strong message that stays with us today and can continue to help provide comfort and inspiration to people around the world facing difficult life circumstances.

About The Children’s Museum of Indianapolis

The Children’s Museum of Indianapolis is a nonprofit institution committed to creating extraordinary learning experiences across the arts, sciences, and humanities that have the power to transform the lives of children and families. For more information about The Children’s Museum, visit http://www.childrensmuseum.org, follow us on Twitter @TCMIndy, Instagram@childrensmuseum, YouTube.com/IndyTCM, and Facebook.

The Children’s Museum of Indianapolis is proud to partner with Riley Children’s at Indiana University Health, Old National Bank and Ice Miller LLP.

Share article on social media or email:

Poms & Associates Offers a Free Webinar about the New Federal Coronavirus Law and Its Impacts on Employers


Poms & Associates logo

Poms & Associates, a full-service insurance brokerage and risk management firm, today announced the availability of a free educational webinar about how the new federal coronavirus law applies to employers.

The first in a series of Poms & Associates webinars about insurance and risk management topics related to the coronavirus pandemic, the one-hour webinar outlines employer impacts of the new federal law, The Families First Coronavirus Response Act (FFCRA). Signed into law on March 18, 2020 and effective since April 2, 2020, FFCRA responds to the COVID-19 outbreak by providing paid sick leave, tax credits and free COVID-19 testing; expanding food assistance and unemployment benefits; and increasing Medicaid funding.

“As the coronavirus situation continues to affect all of us, the critical information that businesses rely on seems to be changing on nearly a daily basis,” said David Poms, founder and president of Poms & Associates. “In an effort to provide access to the most updated and new information as it becomes available, we have put together a series of webinars that can be viewed remotely that highlight issues related to insurance and risk management as our national crisis continues to evolve.”

Presented by Rebecca Torrey, an employment and labor law expert and founding partner of The Torrey Group PC, the webinar highlights two parts of the new law as it applies to employers: expansion of federal family medical leave and new federal emergency paid sick leave. It also covers federal tax withholding and payroll tax credits in the new law that enable funding of paid time off and protections for employees against retaliation for using the new emergency time off.

To view the webinar, go to https://pomsassoc.com/covid19/webinars/. For more information about Poms & Associates, visit https://pomsassoc.com/.

About Poms & Associates

Poms & Associates is a leading full-service insurance brokerage and risk management firm with a proven track record of providing innovative and customized solutions to businesses in high-risk industries. Founded in 1991, the company was built on the premise that knowledge is the best insurance – that is, the best way to help businesses and organizations is to serve not only as an insurance broker but also as an educator about best practices in how to reduce risk and prevent loss before an incident occurs. Poms & Associates today offers a wide range of products and services, including commercial insurance, risk management, loss prevention, employee benefits, corporate wellness and private services for high net-worth individuals. With an annual revenue of more than $50 million, Poms & Associates is among the top 50 privately-held brokerage firms in the U.S. Headquarted in Los Angeles, it has branch offices in Sacramento, Calif., Walnut Creek, Calif., Albuquerque, N.M. and Dayton, Ohio. For more information, visit https://pomsassoc.com/.

Share article on social media or email:

NeoTract Designates Dr. David Prall as UroLift® Center of Excellence


News Image

“We are proud to name Dr. David Prall as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that David Prall, D.O., Minnesota Urology in Woodbury, MN has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Prall has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. David Prall as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

InBios receives Emergency Use Authorization for its Smart Detect SARS-CoV-2 rRT-PCR Kit for detection of the virus causing COVID-19


InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Smart Detect SARS-CoV-2 rRT-PCR Kit. This real-time PCR test is intended for the qualitative detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19, in human nasopharyngeal, anterior nasal and mid-turbinate nasal swab specimens from individuals suspected of COVID-19 by their healthcare provider. Clinical laboratories that are certified under Clinical Laboratory Improvement Amendments (CLIA) in the U.S. can immediately begin using this kit, which offers results in about 4 hours. This kit has been validated on the popular Applied Biosystems 7500 Fast Dx Real-Time PCR and the Biorad CFX96 Touch Real-Time PCR Detection System instruments.

Dr. Syamal Raychaudhuri, InBios’ chief scientific officer, said, “From the very early days, we (InBios) have been quick to respond to emerging global public health threats such as Zika, dengue and West Nile virus, but also cautious to only release products we are confident are of the highest performance and quality. The Smart Detect SARS-CoV-2 rRT-PCR Kit upholds our commitment to these high standards during this time when it is critical to meet the need for accurate testing for COVID-19.”

The Smart Detect SARS-CoV-2 rRT-PCR Kit is available to order immediately. It is the first of several diagnostic test kits being released by InBios to help diagnose COVID-19. In the coming weeks, serology kits for antibody detection will be available, which could help expand and contribute to a wider testing of the population that may be infectious for SARS-CoV-2 virus.

InBios is ramping up production of its COVID-19 diagnostic tests to meet the worldwide need. In 2018, InBios relocated to a larger, modern facility in South Lake Union area of Seattle, Washington, and has successfully increased production capacity and automation to support the ever-increasing demand for its high quality kits to support diagnostic testing during outbreaks of Zika, dengue, West Nile virus and now COVID-19.

While the Smart Detect SARS-CoV-2 rRT-PCR Kit has not been FDA cleared or approved, it has been authorized for use by the FDA under an EUA, which permits use of certain medical products that may be effective during a public health emergency, which was declared for COVID-19 on Jan. 31, 2020. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

For more information about InBios COVID-19 tests, visit: https://inbios.com/covid-19/

For more information on COVID-19, please visit http://www.cdc.gov or http://www.who.int

About InBios

InBios International Inc. specializes in the design, development and manufacture of diagnostic devices for emerging infectious diseases and biothreats. Founded in 1996 in Seattle, WA, our superior quality products are accurate, easy to use and cost effective. InBios offers an extensive catalog of life science reagents, along with a portfolio of more than 25 diagnostic products, including FDA-cleared ELISA kits for Zika, dengue, and West Nile and rapid test kits for Chagas and leishmaniasis. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified.

Share article on social media or email:

Wash Hands Anywhere with Cambro’s Handwash Starter Station


The Handwash Starter Station is ideal for any essential business that is making the hygiene and safety of their employees a top priority.

Promote hygiene anywhere by making handwashing readily available with Cambro’s economic Handwash Starter Station. Lightweight and easy to move, the Handwash Starter Station can be set up anywhere inside or outside your operation. The Handwash Starter Station is ideal for any essential business that is making the hygiene and safety of their employees a top priority. Enabling employees to wash their hands closer to their workstations encourages more frequent handwashing and decreases the spread of bacteria.

During the COVID-19 pandemic, the CDC suggests cleaning hands “after you have been in a public place and touched an item or surface that may be frequently touched by other people, such as door handles, tables, gas pumps, shopping carts, or electronic cashier registers/screens, etc.” For many essential employees, frequently touching items and surfaces like the ones described is unavoidable. Cambro’s Handwashing Starter Station allows businesses to support the safety of their employees by providing increased sanitation in their facilities.

The Handwash Starter Station includes a 22 qt. Dispenser with Spigot and a 22 qt. Pail with Bail for collecting wastewater. Two “hand washing only” stickers clearly identify containers’ sanitation-only function. Both pails are designed with shatter and stain resistant plastic that withstands -40°F to 160°F (-40°C to 70°C) and molded-in handles and bails for easy lifting. We recommend using the Handwash Starter Station in conjunction with the Cambro KD Cart. Set up the Dispenser with Spigot on the top shelf of the KD Cart with the Pail with Bail directly underneath dispenser.

About Cambro Manufacturing

Cambro Manufacturing is a leading manufacturer and distributor of equipment and products to the foodservice industry worldwide. Brothers William and Argyle Campbell founded Cambro in 1951 with a small factory in Huntington Beach, Calif. More than 60 years later, Cambro is still a family-owned and privately held company committed to innovation, quality and value. More information on Cambro is available at http://www.cambro.com.

###

Share article on social media or email: